CA2380981A1 - Derives de fluorene - Google Patents

Derives de fluorene Download PDF

Info

Publication number
CA2380981A1
CA2380981A1 CA002380981A CA2380981A CA2380981A1 CA 2380981 A1 CA2380981 A1 CA 2380981A1 CA 002380981 A CA002380981 A CA 002380981A CA 2380981 A CA2380981 A CA 2380981A CA 2380981 A1 CA2380981 A1 CA 2380981A1
Authority
CA
Canada
Prior art keywords
compounds
formula
atoms
acid
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380981A
Other languages
English (en)
Inventor
Wolfgang Stahle
Simon Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2380981A1 publication Critical patent/CA2380981A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composés de formule (I) dans laquelle R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, m et n possèdent la signification figurant dans la revendication 1, ainsi que leurs sels et solvates physiologiquement acceptables, qui peuvent être utilisés comme inhibiteurs d'intégrine, en particulier pour la prophylaxie et le traitement de troubles de la circulation, de la thrombose, de l'infarctus du myocarde, des coronaropathies, de l'artériosclérose, de l'ostéoporose, de processus pathologiques qui sont entretenus ou propagés par l'angiogenèse, ainsi que dans la thérapie des tumeurs.
CA002380981A 1999-08-07 2000-07-26 Derives de fluorene Abandoned CA2380981A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19937394A DE19937394A1 (de) 1999-08-07 1999-08-07 Fluorenderivate
DE19937394.9 1999-08-07
PCT/EP2000/007153 WO2001010841A2 (fr) 1999-08-07 2000-07-26 Derives de fluorene

Publications (1)

Publication Number Publication Date
CA2380981A1 true CA2380981A1 (fr) 2001-02-15

Family

ID=7917613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380981A Abandoned CA2380981A1 (fr) 1999-08-07 2000-07-26 Derives de fluorene

Country Status (18)

Country Link
EP (1) EP1208088A2 (fr)
JP (1) JP2003506439A (fr)
KR (1) KR20020012631A (fr)
CN (1) CN1368962A (fr)
AR (1) AR025042A1 (fr)
AU (1) AU6828600A (fr)
BR (1) BR0013083A (fr)
CA (1) CA2380981A1 (fr)
CZ (1) CZ2002298A3 (fr)
DE (1) DE19937394A1 (fr)
HK (1) HK1049006A1 (fr)
HU (1) HUP0202464A3 (fr)
MX (1) MXPA02001297A (fr)
NO (1) NO20020592L (fr)
PL (1) PL353054A1 (fr)
SK (1) SK1402002A3 (fr)
WO (1) WO2001010841A2 (fr)
ZA (1) ZA200201873B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101102808B1 (ko) * 2010-04-13 2012-01-05 윤태삼 라이저 인장 장치
US8574899B2 (en) 2010-12-22 2013-11-05 Vladimir B Serikov Methods for augmentation collection of placental hematopoietic stem cells and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058925A1 (fr) * 1989-06-22 1990-12-23 Moshe Weitzberg Compositions pharmaceutiques et methodes de traitement de l'inflammation
RU95104898A (ru) * 1994-03-31 1996-12-27 Бристоль-Мейерз Сквибб Компани (US) Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний
DE69706407T2 (de) * 1996-03-29 2002-05-29 Searle & Co META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DE19654483A1 (de) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanin-Derivate
CA2214931A1 (fr) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorenes et methode d'utilisation

Also Published As

Publication number Publication date
DE19937394A1 (de) 2001-02-08
CZ2002298A3 (cs) 2002-04-17
HUP0202464A3 (en) 2003-02-28
NO20020592L (no) 2002-04-04
WO2001010841A3 (fr) 2001-09-07
MXPA02001297A (es) 2004-07-16
AU6828600A (en) 2001-03-05
KR20020012631A (ko) 2002-02-16
NO20020592D0 (no) 2002-02-06
HK1049006A1 (zh) 2003-04-25
HUP0202464A2 (hu) 2002-12-28
EP1208088A2 (fr) 2002-05-29
BR0013083A (pt) 2002-04-23
ZA200201873B (en) 2003-08-27
PL353054A1 (en) 2003-10-06
AR025042A1 (es) 2002-11-06
JP2003506439A (ja) 2003-02-18
SK1402002A3 (en) 2002-06-04
WO2001010841A2 (fr) 2001-02-15
CN1368962A (zh) 2002-09-11

Similar Documents

Publication Publication Date Title
CZ424998A3 (cs) Deriváty fenylaminu jakožto integrinové inhibitory
RU2187506C2 (ru) Бициклические ароматические аминокислоты
US6559144B2 (en) Bicyclic amino acids
US6743810B2 (en) Indol-3-yl derivatives
RU2234505C2 (ru) Производные хроменона и хроманона в качестве ингибиторов интегринов
EP1343764B1 (fr) Derives d'uree and d'urethanne en tant qu'inhibiteurs de l'integrine
CA2515727C (fr) Procede de production d'acides amines aromatiques bicycliques et produits intermediaires de ces composes
US6521646B1 (en) Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis
CA2380981A1 (fr) Derives de fluorene
CA2382850A1 (fr) Nouveaux inhibiteurs de .alpha.v.beta.3
US20030187289A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
MXPA98010586A (en) Phenylalanin derivatives as laintegr inhibitors
MXPA01004272A (en) Chromenone and chromanone derivatives as integrin inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued